MAIHUB, a domestic medical artificial intelligence (AI) platform company, announced on the 16th that it has attracted additional Series A investment of a total of 4.5 billion won from Evergreen Investment Partners, Future Play, and Intops Investment. Including this investment, the total investment attracted is approximately 10 billion won.
This investment was participated by major venture capitals (VCs) that have focused on healthcare and deep tech, and is said to reflect a positive evaluation of MyHub's technological prowess and platform expandability.
MyHub is supporting the easy introduction of various medical AI solutions to hospitals and clinics based on its self-developed medical AI integrated platform, ‘maiLink’. This platform features a combination of medical data preprocessing normalization technology, hospital information system (EMR) and picture archiving and communication system (PACS) linkage technology, and automatic patient report generation functions, lowering the entry barrier for AI introduction in medical institutions.
Currently, MyLink has been introduced to more than 500 medical institutions in Korea, and is being evaluated as having high usability, especially in institutions where AI introduction was difficult in the past, such as primary and secondary hospitals.
Based on this investment, MyHerb plans to fully expand into overseas markets while improving its platform for medical institutions. It has already signed business agreements (MOUs) with medical institutions in Southeast Asian countries such as Indonesia, the Philippines, and Malaysia, and is currently conducting local demonstrations. It is also preparing to enter the Middle Eastern and South American markets.
Evergreen Investment Partners Managing Director Lee Hyo-jin said, “MyHerb is a company with platform capabilities and execution power that connects the medical AI ecosystem,” and added, “It has high growth potential, such as going beyond selling single solutions to providing customized packages for medical institutions and expanding the B2B2C model with patients.”
MyHerb CEO Yang Hyeok said, “This investment proves that the MyHerb platform is a trustworthy technology in the medical field,” and added, “Based on our successful experience in Korea, we will continue to expand into overseas markets through localized services.”
- See more related articles
You must be logged in to post a comment.